What is the hypoglycemic effect of metformin sustained-release tablets

For many patients with type 2 diabetes, selecting a drug with stable hypoglycemic effect and controllable side effects is the key to control the disease. Among many oral hypoglycemic drugs, metformin sustained-release tablets have become one of the core drugs for diabetes management due to their unique drug mechanism and clinical efficacy. So, what is the hypoglycemic effect of metformin sustained-release tablets?

What is the hypoglycemic effect of metformin sustained-release tablets? The hypoglycemic effect of metformin sustained-release tablets is mainly achieved through three mechanisms:

inhibits hepatic glucose output, reduces hepatic glucose production, and lowers blood glucose levels from the source.

Enhance peripheral tissue sensitivity: improve the response of muscle, fat and other tissues to insulin, promote glucose uptake and utilization.

regulates intestinal metabolism: mildly inhibits intestinal absorption of glucose, further reducing postprandial blood glucose peak. Clinical studies have shown that metformin sustained-release tablets can significantly reduce fasting blood glucose and postprandial blood glucose, leading to a 1% -1.5% decrease in glycated hemoglobin (HbA1c) levels. This effect is not only applicable to newly diagnosed type 2 diabetes patients, but also effective for patients with long-term poor glycemic control. More importantly, its hypoglycemic effect does not rely on insulin secretion, so the risk of hypoglycemia is low, especially suitable for overweight or obese patients. However, despite significant therapeutic effects, traditional metformin sustained-release tablets still face certain challenges. It needs to be taken 1-2 times a day, and drug release is easily affected by the gastrointestinal environment, leading to fluctuations in blood drug concentration. It is easy to cause gastrointestinal reactions such as nausea, vomiting, and diarrhea, and due to taking medication multiple times a day, there is a high rate of missed doses, which affects long-term efficacy.

Second and Third Generation Metformin Extended Release Tablets - Nida ® (Metformin hydrochloride Extended Release Tablets (III))

Nida ® Metformin is a domestically certified osmotic pump controlled release formulation that has been approved by both China and the United States. Through technological innovation, it further enhances the stability and safety of its hypoglycemic efficacy.

1. High compliance: Maintain blood drug concentration for 24 hours, convenient to use once a day

Although traditional metformin sustained-release tablets can prolong drug release time, there are still fluctuations in blood drug concentration, which may lead to unstable blood sugar control. Nida ® Adopting single chamber osmotic pump technology, laser drilling is performed on the surface of the tablet, and a semi permeable membrane is wrapped around it. The drug is released at a zero order rate (constant speed) using osmotic pressure difference. This design allows the drug to enter the bloodstream continuously and evenly within 24 hours, eliminating the peak valley phenomenon of "high first and then low" in ordinary tablets, once a day, ensuring smooth blood sugar control throughout the day.

2. Less adverse reactions: Improving gastrointestinal tolerance Traditional metformin sustained-release tablets have unstable drug release, which can easily cause gastrointestinal reactions such as nausea and diarrhea, leading to some patients discontinuing the medication. Nida ® The constant release mechanism of the drug reduces local irritation to the gastrointestinal tract and significantly reduces the incidence of adverse reactions. Research shows that its 6-month continuous treatment rate is 40% higher than that of regular tablets, especially suitable for patients with weak gastrointestinal function or irregular lifestyle.

3. International Quality Certification: Safer Medication

Nida ® Certified by the US FDA and China NMPA, the production standards meet the requirements of the Sino US co production line, and the quality is in line with international original drug standards. At the same time, its price is only 60% of the original drug, and it is included in the national medical insurance basic drug catalog, greatly reducing the economic burden on patients.

The above is about the introduction of "how about the hypoglycemic effect of metformin sustained-release tablets". Neda metformin hydrochloride sustained-release tablets provide a safer and more convenient treatment option for patients with type 2 diabetes by virtue of its advantages of 24-hour stable glucose control, low side effects and high compliance.